蜂蜜与黑种草预防SARS-CoV-2医院及社区传播:随机对照试验方案结构化摘要
本研究为随机、安慰剂对照、适应性临床试验,平行组设计,优效性框架,分配比1:1,拟纳入1000名有医院或社区COVID-19暴露史的无症状成人,评估蜂蜜与黑种草(HNS)的预防作用。主要结局为随机化后14天内COVID-19发病率,次要结局包括相关症状发生率、住院、死亡及症状严重程度。试验在巴基斯坦拉合尔进行,已注册NCT04767087。
要点
- HNS组每日每公斤体重接受0.5g生蜂蜜和40mg胶囊化有机黑种草种子,安慰剂组接受空胶囊和30ml 5%葡萄糖水,疗程14天。
- 主要结局为随机化后14天内COVID-19发病率,次要结局包括症状、住院、死亡及症状严重程度。
- 纳入标准为有4天暴露史的无症状成人,高危暴露指未戴口罩距确诊者<6英尺超10分钟,中危指戴口罩同等距离时间。
核心结论
- 该试验旨在评估蜂蜜与黑种草(HNS)对医院或社区COVID-19暴露者的预防作用,目前为方案摘要,尚无疗效结论。
研究设计与样本
- 随机、安慰剂对照、适应性临床试验,平行组设计,优效性框架,实验组与安慰剂组分配比1:1。
- 计划纳入1000名参与者,在巴基斯坦拉合尔的Shaikh Zayed Post-Graduate Medical Institute、Ali Clinic和Doctors Lounge招募。
- 当招募过半时进行中期分析,以评估是否需要调整样本量、疗效和无效性。
- 采用四盲法,参与者、护理提供者、结局评估者和数据分析师均设盲。
- 随机化采用抽签法,并按高危和 moderate 风险暴露分层。
关键数值与推荐
- 干预组每日每公斤体重接受0.5g生蜂蜜和40mg胶囊化有机黑种草种子,安慰剂组每日接受空胶囊和30ml 5%葡萄糖水,疗程14天。
- 主要结局为随机化后14天内COVID-19病例发生率。
- 次要结局包括随机化后14天内COVID-19相关症状发生率、住院、死亡及症状严重程度。
- 高危暴露定义为未戴口罩距确诊病例<6英尺超过10分钟;中危暴露定义为戴口罩距确诊病例<6英尺超过10分钟。
- 所有参与者均接受巴基斯坦国家卫生服务部COVID-19临床管理指南第3.0版的标准治疗。
临床怎么用
- 该方案为预防性干预研究,若证实有效,可能为COVID-19暴露后预防提供天然产物选项,但目前尚无结果,不能用于临床实践。
局限性
- 本文仅为研究方案摘要,未报告任何结果数据,无法评估HNS的实际预防效果。
- 试验计划于2022年2月15日完成,但方案摘要未提供最终结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Considering the therapeutic potential of honey and Nigella sativa (HNS) in coronavirus disease 2019 (COVID-19) patients, the objective of the study is defined to evaluate the prophylactic role of HNS. TRIAL DESIGN: The study is a randomized, placebo-controlled, adaptive clinical trial with parallel group design, superiority framework with an allocation ratio of 1:1 among experimental (HNS) and placebo group. An interim analysis will be done when half of the patients have been recruited to evaluate the need to adapt sample size, efficacy, and futility of the trial. PARTICIPANTS: All asymptomatic patients with hospital or community based COVID-19 exposure will be screened if they have had 4 days exposure to a confirmed case. Non-pregnant adults with significant exposure level will be enrolled in the study High-risk exposure (<6 feet distance for >10min without face protection) Moderate exposure (<6 feet distance for >10min with face protection) Subjects with acute or chronic infection, COVID-19 vaccinated, and allergy to HNS will be excluded from the study. Recruitment will be done at Shaikh Zayed Post-Graduate Medical Institute, Ali Clinic and Doctors Lounge in Lahore (Pakistan). INTERVENTION AND COMPARATOR: In this clinical study, patients will receive either raw natural honey (0.5 g) and encapsulated organic Nigella sativa seeds (40 mg) per kg body weight per day or empty capsule with and 30 ml of 5% dextrose water as a placebo for 14 days. Both the natural products will be certified for standardization by Government College University (Botany department). Furthermore, each patient will be given standard care therapy according to version 3.0 of the COVID-19 clinical management guidelines by the Ministry of National Health Services of Pakistan. MAIN OUTCOMES: Primary outcome will be Incidence of COVID-19 cases within 14 days of randomisation. Secondary endpoints include incidence of COVID-19-related symptoms, hospitalizations, and deaths along with the severity of COVID-19-related symptoms till 14th day of randomization. RANDOMISATION: Participants will be randomized into experimental and control groups (1:1 allocation ratio) via the lottery method. There will be stratification based on high risk and moderate risk exposure. BLINDING (MASKING): Quadruple blinding will be ensured for the participants, care providers and outcome accessors. Data analysts will also be blinded to avoid conflict of interest. Site principal investigator will be responsible for ensuring masking. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): 1000 participants will be enrolled in the study with 1:1 allocation. TRIAL STATUS: The final protocol version 1.4 was approved by institutional review board of Shaikh Zayed Post-Graduate Medical Complex on February 15, 2021. The trial recruitment was started on March 05, 2021, with a trial completion date of February 15, 2022. TRIAL REGISTRATION: Clinical trial was registered on February 23, 2021, www.clinicaltrials.gov with registration ID NCT04767087 . FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). With the intention of expediting dissemination of this trial, the conventional formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines.
引用
- Ashraf S, Ashraf S, Akmal R, et al. Prophylactic potential of honey and Nigella sativa L. against hospital and community-based SARS-CoV-2 spread: a structured summary of a study protocol for a randomised controlled trial. Trials. 2021. PMID: 34526081. doi:10.1186/s13063-021-05510-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。